A Novel Model Based on Necroptosis-Related Genes for Predicting Prognosis of Patients With Prostate Adenocarcinoma

被引:21
作者
Li, Xin-yu [1 ,2 ]
You, Jian-xiong [1 ]
Zhang, Lu-yu [3 ]
Su, Li-xin [1 ]
Yang, Xi-tao [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Intervent Radiotherapy, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Neurosurg, Sch Med, Shanghai, Peoples R China
[3] Zhengzhou Univ, Dept Urol Surg, Affiliated Hosp 1, Zhengzhou, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
prostate adenocarcinoma; necroptosis; prognosis; model introduction; cancer; ANTITUMOR IMMUNE-RESPONSE; NKT CELL;
D O I
10.3389/fbioe.2021.814813
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Necroptosis is a newly recognized form of cell death. Here, we applied bioinformatics tools to identify necroptosis-related genes using a dataset from The Cancer Genome Atlas (TCGA) database, then constructed a model for prognosis of patients with prostate cancer.Methods: RNA sequence (RNA-seq) data and clinical information for Prostate adenocarcinoma (PRAD) patients were obtained from the TCGA portal (http://tcga-data.nci.nih.gov/tcga/). We performed comprehensive bioinformatics analyses to identify hub genes as potential prognostic biomarkers in PRAD u followed by establishment and validation of a prognostic model. Next, we assessed the overall prediction performance of the model using receiver operating characteristic (ROC) curves and the area under curve (AUC) of the ROC.Results: A total of 5 necroptosis-related genes, namely ALOX15, BCL2, IFNA1, PYGL and TLR3, were used to construct a survival prognostic model. The model exhibited excellent performance in the TCGA cohort and validation group and had good prediction accuracy in screening out high-risk prostate cancer patients.Conclusion: We successfully identified necroptosis-related genes and constructed a prognostic model that can accurately predict 1- 3-and 5-years overall survival (OS) rates of PRAD patients. Our riskscore model has provided novel strategy for the prediction of PRAD patients' prognosis.
引用
收藏
页数:13
相关论文
共 27 条
[21]  
Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5
[22]   Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis [J].
Xu, Dafeng ;
Wang, Yu ;
Zhou, Kailun ;
Wu, Jincai ;
Zhang, Zhensheng ;
Zhang, Jiachao ;
Yu, Zhiwei ;
Liu, Luzheng ;
Liu, Xiangmei ;
Li, Bidan ;
Zheng, Jinfang .
BIOSCIENCE REPORTS, 2020, 40
[23]   Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers [J].
Yi, Ming ;
Niu, Mengke ;
Zhang, Jing ;
Li, Shiyu ;
Zhu, Shuangli ;
Yan, Yongxiang ;
Li, Ning ;
Zhou, Pengfei ;
Chu, Qian ;
Wu, Kongming .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[24]   The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 [J].
Yi, Ming ;
Zhang, Jing ;
Li, Anping ;
Niu, Mengke ;
Yan, Yongxiang ;
Jiao, Ying ;
Luo, Suxia ;
Zhou, Pengfei ;
Wu, Kongming .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[25]   Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases [J].
Yuan, Junying ;
Amin, Palak ;
Ofengeim, Dimitry .
NATURE REVIEWS NEUROSCIENCE, 2019, 20 (01) :19-33
[26]   IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures [J].
Zeng, Dongqiang ;
Ye, Zilan ;
Shen, Rongfang ;
Yu, Guangchuang ;
Wu, Jiani ;
Xiong, Yi ;
Zhou, Rui ;
Qiu, Wenjun ;
Huang, Na ;
Sun, Li ;
Li, Xuejun ;
Bin, Jianping ;
Liao, Yulin ;
Shi, Min ;
Liao, Wangjun .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[27]   Alteration of the Antitumor immune Response by Cancer-Associated Fibroblasts [J].
Ziani, Linda ;
Chouaib, Salem ;
Thiery, Jerome .
FRONTIERS IN IMMUNOLOGY, 2018, 9